Alcohol withdrawal medical therapy

Resident Survival Guide

Alcohol Withdrawal Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Alcohol withdrawal from other Diseases
Epidemiology and Demographics
Risk Factors
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Criteria
Alcohol Withdrawal Calculator
History and Symptoms
Physical Examination
Laboratory Findings
CT
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Alcohol withdrawal medical therapy On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Alcohol withdrawal medical therapy All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Alcohol withdrawal medical therapy
CDC on Alcohol withdrawal medical therapy
Alcohol withdrawal medical therapy in the news
Blogs on Alcohol withdrawal medical therapy
Directions to Hospitals Treating Alcohol withdrawal
Risk calculators and risk factors for Alcohol withdrawal medical therapy

For patient information click here.

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aditya Govindavarjhulla, M.B.B.S. [2]

Treatment

• No clinical findings can reliably predict who will or will not develop withdrawal. Risk factors for DTs: Previous DTs or detoxifications, Age >30, high degree of alcohol dependence, duration of abuse, the presence of moderate symptoms (CIWA >14) left untreated and concurrent medical illness are all strongly predictive. These findings should prompt intervention. Time abstinent may be a helpful negative predictor. In one large study, patients who were asymptomatic 36 hours after their last drink did not develop symptoms.

• All patients with alcohol abuse should receive 1mg folate QD, magnesium/ phosphate/potassium/fluid volume repletion and thiamine 100 mg IV/IM x1 then 100 mg QD.

• Treatment of alcohol related seizures is on an as needed basis with benzodiazepines. They tend to be transient phenomenon. phenytoin is ineffective in the management of withdrawal seizures, but may be indicated if another seizure disorder or status epilepticus is present. Long term medical suppression or prophylaxis is not indicated for withdrawal seizures. Neuroleptics lower the seizure threshold and should not be used in these patients; however, haloperidol has been used safely in conjunction with benzodiazepines (BDZs).

• BDZs are the cornerstone of therapy for minor withdrawal, seizures and DTs. Fixed schedule therapy, front loading therapy and symptom-triggered therapy have all been evaluated with similar efficacy. Symptoms triggered therapy was associated with less total administration of drug and shorter length of stay but has only been evaluated in patients without acute comorbid illness or seizures and should be restricted to only this limited group of patients.

• In the medically stable patient with no liver dysfunction 10 mg PO/IV is administered every hour till CIWA <10 or sedated. If the patient is stable but has liver disease, give 2 mg lorazepam IV/PO Q 1H till CIWA <10 or sedated. Calculate the total dose used and give this Q6H for 24 hrs. Use that latter regimen for the unstable patient.

• If CIWA is stable x24 hours then decrease the dose by 20%/day. If there is a history of DTs or seizures or the patient is unstable decrease the dose by 10%/day. Give parentral doses of lorazepam recurrence of withdrawal (CIWA >10).

Supportive Care

Goal - Correction of associated disorders, their treatment, providing support for early recovery and prevention of complications.

• Vital signs have to be corrected first.
  • Heart rate should be controlled.
  • Blood pressure should be maintained using fluids and anti hypertensive medication.
• Identification of comorbid conditions and their treatment.
• A few patients may be dehydrated and they may require intravenous fluid replacement.
  • Care has to be taken to avoid fluid overload which can lead to heart failure or exacerbate underlying heart conditions.
• Chronic alcoholics are depleted in reserves of certain electrolytes like magnesium, phosphate. Care has to be provided in correcting them as they play an important role in body metabolism. Administration of magnesium may improve the overall outcome of the patient.
• Alcoholics are vitamin deficient owing to poor dietary habits. Thiamine and folic acid are of major concern.
  • Patients who are experiencing withdrawal should be administered with multivitamins to support the body metabolism.
  • Use of thiamine 100 mg daily for 30 days during withdrawal is recommended.
  • Thiamine should be administered before glucose as it may further deplete the reserve of thiamine.

Inpatient v/s Outpatient

Treatment to alcohol withdrawal patients can be provided in outpatient and inpatient setup.

Outpatient

• Criteria
  • If there are no signs of severe alcohol withdrawal.
  • If there is no previous history of alcohol withdrawal.
  • If there is a supportive family for the patient.
  • If there is no associated comorbid conditions.
• Potential considerations
  • Patients may be non-complaint to medication.
  • May resolve back to his drinking habits.

Inpatient

• Criteria
  • Severe alcohol withdrawal syndrome.
  • History of alcohol withdrawal symptoms on treatment with outpatient basis.
  • Presence of any other comorbid condition or psychiatric condition.
  • Non supportive family

• Potential considerations
  • Cost of inpatient facilities

Nonpharmacological Treatment

• Providing patient a quiet environment.
• Providing reassurance.
• Motivation for alcohol abstinence.

Pharmacological Treatment

• Benzodiazeipines
  • For patients with severe symptoms of alcohol withdrawal.
  • Diazepam is used initially to control the agitation.
  • Dose of diazepam is tapered later.
  • In patients with liver problems lorazepam may be better drug to use.
• Anticonvulsants
  • Anticonvulsants like carbamazepine are of low significance in case of seizures due to alcohol withdrawal.
  • They can be used if seizures are not controlled by benzodiazepines(diazepam).
  • If a patient suffers two or more alcohol withdrawal seizures or develops status epilepticus, it should be assumed that the seizures are not a result of alcohol withdrawal and should be investigated.
• Anti psychotics
  • Anti-psychotic medication should only be made available to patients experiencing hallucinations where benzodiazepines are not effective.
  • The patient should also be monitored carefully for hypotension.
• Baclofen
  • With the use of baclofen whcih acts upon the GABA-B receptors , doses of diazepam can be reduced.
  • It can be used in alcohol addicts.
• Clonidine
  • It acts upon the alpha 2 receptors is useful in controlling the symptoms of alcohol withdrawal by reducing the adrenergic surge.
  • Clonidine and dexmedetomidine can be used as adjunctive treatment to benzodiazepines.

Withdrawal Regimes

Symptom triggered therapy

• In this regime patients CIWA-Ar score is evaluated hourly or bi-hourly and depending upon the score the treatment is administered.
• Benzodiazepines are used in the treatment
• It limits the use of excessive medication.
• This approach is cost effective and prevent complications.

Fixed schedule therapy

• Fixed dosage of drug is given at scheduled intervals
• Can be used if patient is not in severe withdrawal

Loading dose therapy

• It is used in patients who have experienced seizures during past alcohol withdrawal.
• In this regime doses are tailored for the patient's condition.

Treatment of Complications

• Delirium tremens - benzodiazepines, antipsychotics are used for the treatment.
• Wernicke-Korsakoff’s syndrome - thiamine adminstration
• Covulsions- benzodiazepines are useful, if they are repetitive or status epilepticus develops other causes have to be investigated.
• Failure to manage the alcohol withdrawal syndrome appropriately can lead to permanent brain damage or death.
  • It can be prevented by the administration of NMDA antagonists. The NMDA antagonist acamprosate reduces excessive glutamate causing the symptoms.

Treatment in Special Groups

Pregnancy

• Pregnancy doesn't increase the risk of alcohol withdrawal.
• Medications used to treat alcohol withdrawal may cause some effect on the fetus.
• Benzodiazepines cause less effects on the fetus and are efficient.

Hospitalized patients

• Patients hospitalized for some other illness may undergo alcohol withdrawal.
• Early recognition of symptoms of withdrawal is important.
• Early diagnosis and treatment helps in prevention of complications.